News and Treatment Updates | Page 17 | Aplastic Anemia and MDS International Foundation (AAMDSIF)

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Understanding the Impact of Telomere Length and Mutations on Transplant Outcomes

Originally Published: 08/31/2020

Article Source: External Web Content

Advances in Hematologic Malignancies Issue 12, Summer 2020 — R. Coleman Lindsley, MD, PhD Identifying patients at high risk of fatal treatment toxicity is a central challenge in allogeneic hematopoietic stem cell transplantation (HSCT). More accurate prediction of non-relapse mortality (NRM) risk could inform clinical decisions about timing and approach to HSCT. Short telomere length impairs the cellular response to genotoxic and replicative stress, and limits the regenerative potential of many tissues, including the gastrointestinal mucosa and bone marrow. We recently completed a study that...

Guideline-based indicators for adult patients with myelodysplastic syndromes

Originally Published: 08/25/2020

Article Source: External Web Content

Key Points GBIs are measurable elements for quality of care and are currently lacking for adult MDS patients. We developed a GBI consensus for the domains of diagnosis (n = 14), therapy (n = 8), and provider/infrastructural characteristics (n = 7). Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem cell disorders with an increasing burden on health care systems. Evidence-based MDS guidelines and recommendations (G/Rs) are published but do not necessarily translate into better quality of care if adherence is not maintained in daily clinical practice....

TP53 Mutation Status Possesses Prognostic Implications in MDS

Originally Published: 08/14/2020

Article Source: External Web Content

Patients with myelodysplastic syndromes (MDS) who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations, according to results from a study published in Nature Medicine.1 “In recent years, we have characterized which mutations are present in MDS and have established diagnostic tests that map which mutations are present in every patient. This information is used to guide treatment decisions; this is the vision of precision medicine,” Elli Papaemmanuil, PhD, the senior author of...

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Originally Published: 08/13/2020

Article Source: External Web Content

Background Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who required hospitalisation for COVID-19. Methods This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with laboratory-confirmed and symptomatic COVID-19. Data cutoff for...

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults

Originally Published: 08/12/2020

Article Source: External Web Content

In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia (AML) in older adults. Mikkael A. Sekeres, M.D., from the Taussig Cancer Center at the Cleveland Clinic, and colleagues developed evidence-based guidelines to support patients, clinicians, and other health care professionals in their decisions about AML management in older adults. The recommendations relate to newly diagnosed de novo, treatment-related, and secondary AML in...

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Originally Published: 08/06/2020

Article Source: External Web Content

Abstract Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about management of AML in older adults. (article continued at link)

Oral Hypomethylating Agent Regimen Approved for MDS Improves Outpatient Treatment Options

Originally Published: 08/05/2020

Article Source: External Web Content

In an interview with Targeted Oncology, Guillermo Garcia-Manero, MD, discussed the FDA’s recent approval of oral decitabine and cedazuridine as treatment of patients with myelodysplastic syndromes and the data that supported this decision. In July 2020, the FDA granted approval to the combination of oral decitabine and cedazuridine (Inqovi) as treatment of adult patients with myelodysplastic syndromes (MDS), based on the positive findings from the phase 3 ASCERTAIN clinical trial. The indications for this approval include patients with previously treated or untreated de novo and secondary...

FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML

Originally Published: 08/04/2020

Article Source: External Web Content

The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy. The FDA has granted a fast track designation for aspacytarabine (BST-236) as treatment for acute myeloid leukemia (AML) in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy, according to an announcement from Biosight Ltd.1 “Receiving fast track designation from the FDA is an important...

Outrunning Cancer-Related Fatigue

Originally Published: 07/28/2020

Article Source: External Web Content

When Honora Miller, 53, wondered how to explain her cancer-related fatigue to her son, a friend recommended using an analogy involving spoons. The spoon theory held that Miller would start each day with a certain number of the utensils, each one representing energy. Each daily activity cost a spoon. “Let’s say I only have 10 spoons today, but I do more than I should, in a sense borrowing from tomorrow’s spoons. I know that tomorrow will have to be a rest day because I won’t have enough spoons,” Miller says she told her son. “It has become a shorthand for us. My 14-year-old understands that...

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant

Originally Published: 07/06/2020

Article Source: External Web Content

ABSTRACT While hematopoietic cell transplant from an HLA-matched unrelated donor is potentially curative for hematologic malignancy, survival is lower for African Americans compared to Caucasians. As only about 20% of African Americans will have an HLA-matched unrelated donor many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. Thus, the current analyses studied transplant-outcomes after HLA-haploidentical relative (n=249) and umbilical cord blood (n=118) transplants for African Americans with hematologic malignancy between 2008 and 2016. The...